PFIZER INC Available-for-sale Securities, Gross Realized Gains (Losses), Sale Proceeds (Deprecated 2018-01-31)
PFIZER INC (PFE) reported Available-for-sale Securities, Gross Realized Gains (Losses), Sale Proceeds (Deprecated 2018-01-31) of $5.10 billion for the 12-month period ending 2017-12-31, per its 10-K filed 2018-02-22.
Discontinued › Income Statement › Other Income
us-gaap:AvailableForSaleSecuritiesGrossRealizedGainsLossesSaleProceeds · last filed 2018-02-22
- PFIZER INC available-for-sale securities, gross realized gains (losses), sale proceeds (deprecated 2018-01-31) for fiscal 2017 was $5.10B, a 50.00% decline from fiscal 2016.
- PFIZER INC available-for-sale securities, gross realized gains (losses), sale proceeds (deprecated 2018-01-31) for fiscal 2016 was $10.20B, a 137.21% increase from fiscal 2015.
- PFIZER INC available-for-sale securities, gross realized gains (losses), sale proceeds (deprecated 2018-01-31) for fiscal 2015 was $4.30B, a 57.84% decline from fiscal 2014.
- PFIZER INC available-for-sale securities, gross realized gains (losses), sale proceeds (deprecated 2018-01-31) for fiscal 2014 was $10.20B, a 32.89% decline from fiscal 2013.
| Period end | Available-for-sale Securities, Gross Realized Gains (Losses), Sale Proceeds (Deprecated 2018-01-31) 12 month |
|---|---|
| 2017-12-31 | $5.10B 10-K · filed 2018-02-22 |
| 2016-12-31 | $10.20B 10-K · filed 2018-02-22 |
| 2015-12-31 | $4.30B 10-K · filed 2018-02-22 |
| 2014-12-31 | $10.20B 10-K · filed 2017-02-23 |
| 2013-12-31 | $15.20B 10-K · filed 2016-02-29 |
| 2012-12-31 | $19.00B 10-K · filed 2015-02-27 |
| 2011-12-31 | $10.20B 10-K · filed 2014-02-28 |
| 2010-12-31 | $5.30B 10-K · filed 2013-02-28 |
| 2009-12-31 | $27.00B 10-K · filed 2012-02-28 |
| 2008-12-31 | $2.20B 10-K · filed 2011-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |